A survey of new Rx, new generic, and new OTC products
Q&A: Challenges Health Systems May Face When Integrating Biosimilars
A conversation with Chelsee Jensen, PharmD, BCPS, director of formulary management at the Mayo Clinic.
The Current, Future Roles of AI within the Pharmacy Profession
As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.
FDA Approves Omalizumab-Igec as First Interchangeable Biosimilar to Xolair
Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.
The Unique Challenges, Growth in the Business of Health-System Pharmacy
From market pressures to regulatory framework, Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed growth in the business of health-system pharmacy and the challenges it has faced.
FDA Approves neffy for Treatmet of Type 1 Allergic Reactions, Anaphylaxis
The approval is the first significant innovation for the delivery of epinephrine for this population in more than 35 years, according to the company news release.
FDA Approves Denosumab-Bmwo as Biosimilar to Prolia, Xgeva
Denosumab-Bmwo is approved for all indications of the respective reference products, including osteoporosis and high-risk of fracture due to chemotherapy.
